Article | April 11, 2024

Ophthalmic Drug Delivery

Source: Nanoform

By Dr. Tamas Solymosi, Lead Scientist, Nanoform


The human eye, though vital for sight, poses a significant challenge for delivering medications. While ophthalmic drug delivery, the process of administering drugs directly to the eye, offers the potential for targeted treatment and reduced side effects, the eye's complex structure and protective barriers create hurdles. This is particularly concerning considering the WHO reports at least 2.2 billion people globally experience visual impairment [1]. Age-related macular degeneration (AMD), diabetic retinopathy (DR), and ocular infections are just a few conditions that can severely impact vision and quality of life.

Fortunately, ophthalmic drug delivery holds promise. The eye provides a direct route to the target site, enabling localized treatment and minimizing systemic side effects. Additionally, this approach can offer a rapid onset of action and improve patient compliance, making it a valuable tool for managing various ocular diseases. However, effective delivery has its difficulties. This article delves into the challenges of ophthalmic drug delivery, explores its intricacies, and examines the potential of nanoparticles as a game-changing technology for ocular drug-delivery systems (DDS).

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Advancing RNA? Subscribe today.

Subscribe to Advancing RNA X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Advancing RNA